Search
for
Sort by
Research 61–90 of 585
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- The Role of Janus Kinase Inhibitors in Dermatology
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
- JAK inhibitors in dermatology: The promise of a new drug class
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician